Therefore, targeting the cGAS-MITA/STING pathway can have potential therapeutic benefits in patients with one of several neurodegenerative disorders, including Alzheimer’s disease [174], Parkinson’s disease [175], and amyotrophic lateral sclerosis (ALS) [49]. The gene discussed is STING1; the disease is early-onset autosomal dominant Alzheimer disease.